Tumor Associated Antigens Articles & Analysis: Older
32 news found
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs ...
ByBayer AG
Anti-SIRPα mAb ES004 potently potentiates antibody dependent cellular phagocytosis (ADCP) activity of antibodies against tumor associated antigens (TAAs) in vitro and in vivo. Highlights: ES004 recognizes pan-allele human SIRPα with high affinity ES004 binds to a unique epitope on the CD47 binding domain of SIRPα ES004 ...
According to the official speaker from Creative BioMart, based on MHC-like complexes that can directly identify and isolate antigen-specific T cells or screen and identify MHC-like antigens that can be used for vaccine development, the company can provide two therapeutic development services: cell therapy and vaccine development. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 ...
Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...
ByArdigen
“Clinical data previously collected by Cancer Research UK demonstrated peripheral immunogenicity in patients with NSCLC treated with VAC2, providing support to the underlying mechanism of using allogeneic dendritic cells to present tumor-associated antigens to the body’s immune system. Simultaneous with Cancer Research UK efforts to ...
“Specifically, the ability of our technology to target tumor self-antigens and induce a potent T cell response that leads to tumor regression is important as we prepare to file an IND for our HB-300 program in prostate cancer in the third quarter. ...
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor ...
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab ...
ByScancell
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with advanced colorectal (bowel) cancer ...
Under the terms of the agreement, Zephyr will employ its proprietary AI and machine learning technology to identify targets suitable for activating T-cell-mediated anti-tumor responses. Specifically, Zephyr will evaluate a range of molecular and genetic data through in silico target discovery to uncover known, high potential tumor-associated ...
GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer ...
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Corporation ...
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results ...
LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ...
These glycoproteins are often involved in cell recognition and can serve as surface markers or surface antigens for a particular cell or cells at a particular stage. 3. ...
Abera Bioscience AB (“Company” or “Abera”) initiated research and development in immuno-oncology in 2021 with a first sub-goal to explore the potential of the company’s platform in the area and to carry out initial studies for further prioritization. In accordance with the press release regarding a private placement sent out December 23rd, in which Abera informed ...
In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of ...
We are glad to announce that scientists from our biotechnology company BlueSky Immunotherapies GmbH (Ltd.) have achieved great success in completely and permanently eliminating equine sarcoids and bovine papillomavirus that causes this aggressive form of skin cancer that horses often suffer from. By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector ...
TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4). ...